If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Editas Medicine (EDIT – Research Report) yesterday and set a ...

Recent TAU study demonstrates how a crucial but underexplored process of DNA transfer between bacteria affects its defense ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Hold rating on Y-Mabs Therapeutics (YMAB – Research ...

In gene and cell therapy, RNP-mediated CRISPR gene editing is quickly emerging as the new norm. For many gene editing firms, GenScript has created hundreds of Cas9, Cas12a, Cas13a, MAD7 ...

Genetic changes are a significant cause of infertility, impacting over 15% of the global population. TLE6, a major protein ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Researchers have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal neurodegenerative condition. The treatment, which uses ...

CRISPR gene-editing technology presents a possible solution for feeding a growing population, but incorporating CRISPR into ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...